MedTrace Logo

Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne

NCT01106807 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2021-02-18

No results posted yet for this study

Summary

The purpose of the study is to evaluate the efficacy of CD07223 1.5% Gel and 0.5% gel in reducing inflammatory, non-inflammatory, and total acne lesion counts after 6 weeks of twice daily applications. The study will also evaluate the safety of the study products using tolerance and adverse event data.

Conditions

Interventions

DRUG

Epiduo vehicle gel

500 microliters of Epiduo vehicle gel on one half-face twice daily for six weeks

DRUG

CD07223

500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks

DRUG

CD07223

500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks

DRUG

Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel

500 microliters Epiduo Gel on one of the half-face for the morning dose

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Principal Investigators

  • Michael Graeber, MD · Galderma R&D

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01106807 on ClinicalTrials.gov